Summary of Key Points
China's generic pharmaceutical industry is facing a triple squeeze from domestic centralized procurement driving down prices, the high cost of regulatory approval processes, and overseas tariffs and regulations, which are crushing the old business model (low-cost competition domestically and profit margins from exports). The United States, in pursuit of drug sovereignty, is trying to force the return of generic production capacity through measures such as tariff escalations and priority review processes. However, it faces three major challenges: high costs, long implementation times, and a supply chain that relies heavily on China and India. Although China's generic pharmaceutical industry may seem to be on the decline, its core capabilities (including raw material production, compliance systems, and skilled engineers) remain. In the future, the industry plans to integrate into the global supply chain by establishing factories overseas and shifting towards higher-end products.
I. The Decline of China's Generic Pharmaceutical Industry: Three Pressures Crushing the Old Business Model
The decline of China's generic pharmaceutical sector is not due to a single factor but rather the combined effect of three major issues:
1. Centralized Procurement Driving Prices Down: National centralized procurement has reduced the prices of common drugs by more than 70%, with some essential medicines seeing price cuts of up to 90%. This results in minimal profits, or even losses for manufacturers. Failing to win bids means losing access to public hospital markets, forcing small and medium-sized pharmaceutical companies to either withdraw from the market or go bankrupt. Additionally, there is an overabundance of generic drug approvals; for example, there are over 800 approval numbers for levofloxacin alone, and in 2026, 43 generic drug applications were rejected within just three days.
2. High Costs of Regulatory Approval: To ensure that generic drugs are as effective as their brand-name counterparts (under the consistency evaluation requirements), companies need to invest millions of yuan. For complex drugs, these costs can be even higher. However, the annual sales for some selected products may only amount to a few million yuan, making such investments unprofitable and leading to shortages of essential medicines.
3. Blockade on Export Routes: Profits from exports to the United States were already slim, and now with tariffs rising from 0% to 100% and then to 200%, along with the requirement for full traceability of the entire supply chain (including raw materials, intermediates, and finished products), the old model of competing on low prices domestically and earning a profit margin through exports is no longer viable.
II. The US Efforts to Repatriate Production: Not a Complete Return of the Entire Supply Chain
The US's call for repatriation of production is not a whim but stems from concerns about its dependence on overseas markets (over 50% of its drugs are produced abroad, with China accounting for 22% of the raw materials used). Its goals are clear:
- Which Products to Target: Priority is given to 86 essential medicines such as insulin, ibuprofen, and antibiotics, as well as large-volume drugs purchased by the federal government; less attention is paid to less common drugs.
- Which Parts of the Supply Chain to Control: The US focuses on gaining control over raw materials and the final formulation and packaging processes, avoiding high-cost steps like intermediation and fermentation due to higher environmental and labor costs in the US.
- How to Achieve This: A combination of tactics is used: tariff threats to encourage companies to relocate, priority review processes for domestic production, assistance with factory establishment (through the PreCheck pilot program), and preferential government procurement. The ultimate goal is to persuade companies to make the decision voluntarily.
III. The Three Insurmountable Challenges in the US's Repatriation Plan
Despite the US's efforts, there are several significant obstacles:
1. Cost Issues: Importing drugs will become more expensive due to higher labor costs and stricter environmental regulations. If tariffs of 200% are implemented and imports are disrupted, domestic prices will rise, posing a challenge for consumers and the government, which is likely to opt for exemptions or delays.
2. Time Constraints: Building compliant raw material production facilities takes 3-5 years, and even longer for complex products like antibiotics. China's dominance in this area (thanks to chemical parks and skilled engineers) has been built over 20 years. The US will not be able to fill the gap in insulin and ibuprofen production until at least 2029, during which it will still rely on China and India.
3. India's Role: While 40% of US generic drugs are made in India, India itself relies heavily on Chinese raw materials. For the US to reduce its dependence on China, it would first need to help India become self-sufficient in this regard. This is a more difficult task than simply repatriating production.
IV. Counterintuitive Results: Despite the Decline of China's Generic Industry, the US Faces Greater Challenges
Although China's generic pharmaceutical industry's profits have declined, its core capabilities remain intact. The US lacks these resources and faces geographical limitations in attracting Chinese talent. As a result, a strange scenario has emerged where Chinese companies (such as Huahai and WuXi AppTec) are establishing factories in the US or Mexico with US subsidies, effectively using American funds to build production capacity while still relying on Chinese technology and supply chains.
V. Future Prospects: A Three-Year Buffer Period Leading to a Multi-Center Supply Chain
- 2026-2028 (Buffer Period): The US will maintain zero tariffs, and Chinese companies will accelerate the establishment of factories in Mexico and Southeast Asia to avoid future tariff increases. Exports of pharmaceutical formulations to the US will increase slightly, while exports of raw materials will face pressure.
- 2028-2029 (Critical Point): If tariffs are implemented, the US market will become more segmented, with essential drugs produced domestically at higher costs with government subsidies, and complex drugs relying on India and China for nearshore distribution. Domestic centralized procurement will shift to focus on first-time approvals and complex formulations (such as sustained-release and special injectables) as profit drivers.
- Long Term: The global supply chain will evolve from a "China-centric" model to a multi-center structure involving China, India, Mexico, and the US. China's market share will decline but not disappear completely, with a shift towards producing raw materials, specialized intermediates, and higher-end generic drugs. Low-end oral tablets will continue to be phased out.
In summary, what is being "forced to decline" is the old business model based on low-cost competition and export-driven profit margins, not China's generic pharmaceutical industry as such. The US's attempt to repatriate production faces insurmountable challenges, and it is unlikely to achieve its goals of producing drugs at home at low costs while completely decoupling from China. China's future strategy will involve transforming its manufacturing capabilities into compliant facilities overseas and specializing in certain products, while continuing to integrate into the global supply chain through higher-end generic drugs.